CTOs on the Move

Sight Sciences

www.sightsciences.com

 
Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world`s most prevalent eye diseases. The company`s surgical glaucoma product portfolio features the OMNI Surgical System, a dually indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm`s canal and collector channels) with a single device and single corneal incision. The company`s non-surgical dry eye product portfolio consists of the TearCare for ophthalmologists ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Funding

Sight Sciences raised $10M on 10/12/2017
Sight Sciences raised $31M on 09/04/2019
Sight Sciences raised $30M on 03/18/2020
Sight Sciences raised $23.2M on 12/09/2020

Similar Companies

Alliance Medical Services

Alliance Medical Services is a Holland, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Hans Rudolph Inc

Hans Rudolph Inc is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medical Extrusion Technologies

Medical Extrusion Technologies is a Murrieta, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Orthopaedic Solutions

Orthopaedic Solutions is a Columbia, SC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioject

Bioject Medical Technologies Inc. is a leader in the development of needle-free injection therapies with over 25 years of experience improving the administration of liquid medications; pharmaceuticals, vaccines, and biologics. Bioject's technology works by forcing liquid medication at high speed through a tiny orifice held against the skin. This creates an ultra-fine stream of fluid that penetrates the skin, delivering medication in a fraction of a second. Bioject's systems are designed to deliver injected medications comfortably, accurately, and quickly - without the use of a needle. Bioject was founded in 1985 to develop needle-free injection systems to improve the comfort and safety of routine injections. From its early work focused on improving the characteristics of these delivery systems, the Company has created a broad technology platform for delivering a wide range of medications and vaccines to the subcutaneous, intramuscular and intradermal depths. Bioject has developed a portfolio of injection systems based on its core technology, the foundation for which is more than 80 issued and pending patents and an extensive body of technical know-how. These include durable devices designed for heavy use in a professional healthcare environment, and small, lightweight injectors designed for home use. With partners, Bioject is also developing inexpensive, pre-filled, disposable injection systems. Further validating its technology, Bioject and its partners have the largest volume of published studies using needle-free injection technology systems. Bioject's strategy is to form strategic partnerships with pharmaceutical, biotechnology, and animal health companies. The result is mutually beneficial agreements with these partners to develop customized injection systems to enhance the delivery of their injected medication or vaccine. Bioject has alliances with leading pharmaceutical, biotechnology, and animal health companies. Bioject's products are also used in public health, Physicians offices, and in cutting edge biomedical research at leading institutions around the globe.